Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 + pembrolizumab + gemcitabine for metastatic pancreatic cancer
ISRCTN53212600Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of IMM-101, pembrolizumab and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Objective response rate. Started Jun 2024; status: terminated.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN53212600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53212600.